Quick Answer
Nuvectis Pharma, Inc. reported Research And Development Expense of $18.15 million for the year ending 2025.
- Nuvectis Pharma, Inc. showed an increase of +40.5% in Research And Development Expense from 2024 to 2025.
- This data is from Nuvectis Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on February 11, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $4.25 million | Q3 2021: $4.16 million | Q1 2022: $1.81 million | Q2 2022: $2.51 million | Q3 2022: $4.52 million | Q1 2023: $2.37 million | Q2 2023: $4.26 million | Q3 2023: $4.49 million | Q1 2024: $2.66 million | Q2 2024: $2.94 million | Q3 2024: $2.82 million | Q1 2025: $3.68 million | Q2 2025: $3.61 million | Q3 2025: $5.77 million.
- Over the full 5 years of available data (2021 to 2025), Nuvectis Pharma, Inc.'s Research And Development Expense has grown by 90.2%.
- Historical annual values: Fiscal year 2025: $18.15 million | Fiscal year 2024: $12.92 million | Fiscal year 2023: $15.38 million | Fiscal year 2022: $13.23 million | Fiscal year 2021: $9.55 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: